Appointments at INC Research, PPD, Catalent, Celerion, Pharmanet and CIToxLAB – People on the move
INC Research has appointed Chris Smyth to its oncology leadership team as senior vice president of clinical development.
Prior to joining INC, Smyth specialized in the development of small molecules, biologicals and DNA aptamers for the treatment of cancer.
Edward Ian has joined PPD as vice president of clinical development for the Asia Pacific region. He will be based in Singapore and will have oversight of the CROs Phase II-IV region.
Catalent Pharma Solutions has hired Barry Littlejohns as president of medication delivery solutions.
Littlejohns is returning to Catalent having served as senior VP of operations and business development at Genmab for the last two years.
Celerion has named Raymond Farmen as VP of global bioanalytical services. He will have responsibility for the company’s bioanalytical operations in Zurich, Switzerland and Lincoln, Nebraska USA.
Prior to joining Celerion, he held executive positions at PharmOptima, Eurofins AvTech Laboratories, Camargo Pharmaceutical Services, MDS Pharma Services, Phoenix International Life Sciences and Bristol-Myers Squibb.
Preclinical CRO CiToxLAB has added Paul Barrow and Francois Spezia to its executive team. Spezia will head the firm's reproductive toxicology department, while Barrow has been appointed as director of scientific projects and client consulting.
Barrow joins the company after serving ten years as a director of toxicology at Ricerca Biosciences and Spezia previously worked at Pfizer, Chanel and HMR.
PharmaNet Development Group has Joel Posener as executive medical director of its neuroscience business.
Prior to joining PharmaNet he held roles at Wyeth as senior director of neuroscience medical research and early development and clinical pharmacology.
